Modern Phytotherapy in Patients with Benign Prostate Hyperplasia and Chronic Prostatitis
Authors: Nikitin Oleh , Sych Volodymyr , Yasynetskyi Mykola 
Published: June 2023

Treatment of prostate diseases remains one of the priorities in modern medicine. The patients with chronic inflammation and benign prostate hyperplasia (BPH) have a larger volume of the gland, more pronounced clinical manifestations of the disease and a higher probability of acute urinary retention development.
The choice of the medication treatment of BPH and chronic prostatitis (CP) is under the influence of many factors, namely: the nature of clinical manifestations of the disease, the volume of adenomatous tissue, the severity and features of urinary disorders and disorders of the functional state of the bladder.
Plant medications are very popular in many countries of the world, primarily due to the minimal severity of side effects.
The objective: to analyze the efficacy and tolerability of dietary supplements in the treatment of patients with BPH and CP.
Materials and methods. 90 patients with BPH stage I-II were involved in the study, the average age and the duration of the disease were practically similar. Patients were divided into two groups depending on the treatment. The main group included 56 men who received a medication produced by company “BEHEALTH” for condition improvement of CP and BPH. This drug includes all the components listed in the “Phytotherapy” section of Recommendations of the Treatment of the European Association of Urology (2019). The comparison group included 34 patients who received a monocomponent medication.
The tolerance of the product in patients of the main group was evaluated on the basis of subjective sensations and objective data during the treatment.
Results. After the treatment the patients in both groups had an improvement in the clinical condition, taking into account the main complaints (intermittent and weakening of a jet of urine, feeling of incomplete emptying of the bladder, polakiuria, imperative urges). After 3 months of treatment in the main group the maximum rate of urination increased significantly, dysuria symptoms decreased.
In 7 patients of the main group (30±10%) with the output volume of up to 80 ml and the volume of residual urine up to 150 ml after the treatment, the largest and significant decrease in the volume of residual urine on average up to 40±6 ml (p<0.05) was established. QOL decreased by 9.13 % (p>0.05), prostate volume – by 13.3 % (p>0.05), maximum and average urination rate increased (9.1 % and 14.6 % respectively; p>0.05).
Treatment has ensured effective elimination of symptoms of lower urinary tract caused by BPH, which is confirmed by clinical improvement in 94.1 % of patients in the main group.
Conclusions. As a result of the study, the effectiveness of the medication produced by company “BEHEALTH” for condition improvement by CP and BPH in the treatment of patients with benign prostate hyperplasia (BPH) and chronic prostatitis (CP) both objective and subjective indicators was determined (IPSS and QOL).
Phytotherapy has demonstrated its high efficiency and safety in the treatment of BPH, in particular in relieving the symptoms of CP, preventing the progression of the disease, improving the patient’s quality of life and the minimum level of side effects, which allows it to be used for a long time.